Rob Ter Heine

35PUBLICATIONS
93CO-AUTHORS
HaematologyCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Pharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (35)

|Jun 14, 2026
Exploring individualized crovalimab dosing in PNH through in silico modelling: Potential for improved convenience and cost efficiency.

|May 13, 2026
Deprescribing opportunities for patients with advanced non-small cell lung cancer: an observational study of potentially inappropriate medications and stakeholders' perspectives.

|Nov 06, 2025
Optimizing lazertinib therapy through GSTM1 genotyping: a strategy to reduce excess drug exposure and potential toxicity.

Rob Ter Heine, Bianca J C van den Bosch, Robin M van Geel

|Sep 10, 2025
Eco Friendly and Budget Smart: An Economic and Environmental Evaluation of Alternative PD-1 and PD-L1 Inhibitor Dosing Regimens.

Leo Karlsson, Joseph Ciccolini, Rob Ter Heine

|Jul 25, 2025
TDM-Based Tailored Dosing of Durvalumab in Lung Cancer Patients: A Comprehensive Population Pharmacokinetic-Pharmacoeconomic Evaluation.

Fenna de Vries, Eric J F Franssen, Arthur A J Smit

|Jun 22, 2025
Population pharmacokinetics and optimized dosing of cefuroxime in critically ill patients.

Jaap W A Mouton, Julian D Machiels, Arthur M A Pistorius

Pageof 6

Frequent Collaborators

6 joint publications

Roger J M Brüggemann

4 joint publications

David M Burger

4 joint publications

Michel van den Heuvel

4 joint publications

Nikki de Rouw